Furthermore, the combination of a TOPK inhibitor with sunitinib has been shown to enhance the sensitivity of sunitinib-resistant renal cancer cells, suggesting that phosphorylated TOPK could be a promising biomarker for predicting sunitinib resistance [13]. Here, PBK is linked to renal carcinoma.